Summary
Global Markets Direct’s, ‘Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016’, provides in depth analysis on Mycobacterium tuberculosis Protein Ag85A targeted pipeline therapeutics.
The report provides comprehensive information on the Mycobacterium tuberculosis Protein Ag85A, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Mycobacterium tuberculosis Protein Ag85A
- The report reviews Mycobacterium tuberculosis Protein Ag85A targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics and enlists all their major and minor projects
- The report assesses Mycobacterium tuberculosis Protein Ag85A targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mycobacterium tuberculosis Protein Ag85A targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mycobacterium tuberculosis Protein Ag85A
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mycobacterium tuberculosis Protein Ag85A development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Imaxio SA
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mycobacterium tuberculosis Protein Ag85A Overview 6
Therapeutics Development 7
Mycobacterium tuberculosis Protein Ag85A - Products under Development by Stage of Development 7
Mycobacterium tuberculosis Protein Ag85A - Products under Development by Therapy Area 8
Mycobacterium tuberculosis Protein Ag85A - Products under Development by Indication 9
Mycobacterium tuberculosis Protein Ag85A - Pipeline Products Glance 10
Early Stage Products 10
Mycobacterium tuberculosis Protein Ag85A - Products under Development by Companies 11
Mycobacterium tuberculosis Protein Ag85A - Products under Development by Universities/Institutes 13
Mycobacterium tuberculosis Protein Ag85A - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Mycobacterium tuberculosis Protein Ag85A - Companies Involved in Therapeutics Development 20
Imaxio SA 20
Mycobacterium tuberculosis Protein Ag85A - Drug Profiles 21
HG-85A - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
HG-85A/B - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
HG856-A - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
HG856-BCG - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
HG856-SeV - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
IMX-313-TB - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
MVA-85A - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
TB/FLU-04L - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
tuberculosis vaccine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
tuberculosis vaccine - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
tuberculosis vaccine 2 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Mycobacterium tuberculosis Protein Ag85A - Dormant Projects 35
Mycobacterium tuberculosis Protein Ag85A - Discontinued Products 36
Mycobacterium tuberculosis Protein Ag85A - Featured News & Press Releases 37
Mar 24, 2015: World-first TB vaccination trials enter next stage 37
Oct 02, 2013: New tuberculosis vaccine will help fight 'serious public health threat' 38
Sep 03, 2013: Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313, in tuberculosis 39
Feb 04, 2013: Emergent BioSolutions Reports Publication Of Data From Phase IIb Clinical Trial For Tuberculosis Vaccine Candidate MVA85A In Lancet 39
Dec 10, 2012: University Of Cape Town Begins New study On TB Vaccine For Newborns Of HIV-positive Mothers 41
Mar 22, 2012: Emergent BioSolutions Receives NIAID Grant To Support Tuberculosis Vaccine Candidate 41
Aug 11, 2011: Aeras And Oxford-Emergent Tuberculosis Consortium Announce Start Of Phase IIb Trial Of New Investigational Tuberculosis Vaccine In Senegal And South Africa 42
Apr 28, 2011: Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant In Phase IIb Clinical Trial 43
Feb 25, 2011: Delegates From European Parliament Express Support For Rapid Development Of Emergent's New TB Vaccine 44
Apr 22, 2009: New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa 44
Jun 23, 2008: Emergent BioSolutions And University of Oxford Form Joint Venture To Develop Advanced Tuberculosis Vaccine 45
Oct 25, 2004: TB Vaccine MVA85A Succeeds In Safety Trials 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48
List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Imaxio SA, H2 2016 20
Dormant Projects, H2 2016 35
Discontinued Products, H2 2016 36
List of Figures
Number of Products under Development for, H2 2016 7
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Routes of Administration, H2 2016 16
Number of Products by Stage and Routes of Administration, H2 2016 16
Number of Products by Molecule Types, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 18
